IL6 and hepatocellular carcinoma: Likewise, a study conducted by Yu Li and colleagues proposes that IL-6 could potentially serve as a biomarker indicative of response to sorafenib (PubChem CID:216239) treatment among patients with hepatocellular carcinoma (HCC).